内毒素所致急性肺损伤治疗药物研究进展

Research progress of drugs for the treatment of LPS-induced acute lung injury

急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)是临床病死率较高的疾病,其中,革兰氏阴性菌感染相关的ALI所占比例很大,致病因素主要为内毒素(LPS)。ALI发病机制错综复杂,目前仍无特效治疗药物。因此,针对LPS所致急性肺损伤的治疗药物研究受到广泛重视,围绕抗炎、抗凝血、改善肺水肿、抗氧化应激等方面的研究取得了新的进展,一些新型药物如表面活性物质、蛋白酶活性抑制剂、心房利钠肽等在临床上也已取得了一定成效。本文综述了LPS引起肺损伤的治疗药物研发进展,供抗ALI新药研发人员参考。

Acute lung injury/Acute respiratory distress syndrome（ ALI/ARDS） is a kind of disease with high clinical mortality. Among them,the percentage of ALI associated with Gram-negative bacteria infection is very high,the main pathogenic factor of which is endotoxin（ LPS）. The pathogenesis of ALI is so complex that there is no specific treatment drugs. Therefore,the research on the treatment of LPS-induced acute lung injury has been paid more and more attention. And new progress has been made in the areas of anti-inflammatory,anticoagulant,improving pulmonary edema and anti-oxidative stress. Some new drugs such as surfactant,protease activity inhibitors and atrial natriuretic peptide has also achieved some clinical success. In this article,we reviewed treatment drugs of LPS-induced lung injury,which will provide references for the researchers to develop new anti-ALI drugs.